Analyst Serge Belanger of Needham maintained a Buy rating on Liquidia Technologies (LQDA – Research Report), retaining the price target of $25.00.
Serge Belanger has given his Buy rating due to a combination of factors surrounding Liquidia Technologies. The company is approaching a significant milestone with the upcoming PDUFA date for Yutrepia, which is aimed at treating PAH and PH-ILD. This potential approval represents a transformative opportunity for Liquidia, as it could significantly enhance their market position.
Additionally, the discussions at the Needham Healthcare Conference highlighted Yutrepia’s unique advantages over existing treatments like Tyvaso DPI. The differentiation of Yutrepia, coupled with the promising L606 development program, underscores the company’s growth potential. These strategic factors contribute to Belanger’s positive outlook on the stock, leading to the Buy rating.
In another report released on April 7, Bank of America Securities also maintained a Buy rating on the stock with a $22.00 price target.